carbonic acid-(1-chloroethyl-4-nitrophenyl)-ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbonic acid-(1-chloroethyl-4-nitrophenyl)-ester
• 英文别名: [2-(1-chloroethyl)-4-nitrophenyl] hydrogen carbonate
• 化学式: C₉H₈ClNO₅
• 分子量: 245.619
• InChiKey: GNFSJBGVMNEGOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  对硝基苯酚 、 1-氯乙基氯甲酸酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 carbonic acid-(1-chloroethyl-4-nitrophenyl)-ester
  参考文献：
  名称：

  Bicyclic heterocycles, the preparation thereof, and their use as

  摘要：

  本发明涉及公式##STR1##的5-成员杂环融合苯衍生物，其中R.sub.a至R.sub.c，A，X和Y的定义如权利要求1中所定义，其互变异构体，立体异构体，其混合物及其盐，特别是其与具有有价值性质的无机或有机酸或碱的生理上可接受的盐。上述公式I中R.sub.c表示氰基的化合物是制备公式I的其他化合物的有价值中间体，上述公式I中R.sub.c表示以下氨基甲酰基基团之一的化合物及其互变异构体和立体异构体具有有价值的药理学性质，特别是抗血栓活性。

  公开号：

  US06114532A1

文献信息

• Prodrugs of GABA analogs, compositions and uses thereof
  申请人：Gallop A. Mark

  公开号：US20060229361A1

  公开（公告）日：2006-10-12

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，GABA类似物前药的药物组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法以及使用GABA类似物前药的药物组合物治疗或预防常见疾病和/或疾病的方法。
• Administrative agents via the SMVT transporter
  申请人：XenoPort, Inc.

  公开号：US20030158089A1

  公开（公告）日：2003-08-21

  Disclosed herein are conjugates comprising a therapeutic agent (e.g., a drug) which is linked to a conjugate moiety that is itself, or itself in combination with the agent, is a good substrate for the sodium dependent multi-vitamin transporter (SMVT). The conjugates have a molecular weight below 1500 daltons and exhibit increased uptake via SMVT through the cells lining the gastrointestinal lumen, and hence higher bioavailability, when administered orally compared to the therapeutic agent itself Also disclosed are methods of delivering agents that, as a result of linkage to a conjugate moiety, are good substrates of the SMVT transporter. Further disclosed are methods of screening conjugates or conjugate moieties, linked or linkable to a therapeutic agent, for capacity to be transported as substrates through the SMVT transporter.

  本文披露了包含治疗剂（例如药物）的共轭物，该治疗剂与一个共轭基团连接，该共轭基团本身或与该治疗剂结合后是钠依赖性多维生素转运蛋白（SMVT）的良好底物。这些共轭物的分子量低于1500道尔顿，并且通过肠道腔内细胞的SMVT表现出增加的摄取，因此在口服给药时具有更高的生物利用度，与治疗剂本身相比。还披露了通过连接到共轭基团的药剂而成为SMVT转运蛋白的良好底物的传递方法。此外，还披露了筛选共轭物或共轭基团的方法，这些共轭物或共轭基团与治疗剂连接或可连接，具有作为底物通过SMVT转运蛋白进行转运的能力。
• Novel prodrugs for antimicrobial amidines
  申请人：——

  公开号：US20020019437A1

  公开（公告）日：2002-02-14

  A methods of treating an infection comprises administering a therapeutically effective amount of a compound described by the Formula (I): 1 wherein: X may be O, S, or NR′ wherein R′ is H or loweralkyl; R 1 and R 2 may be independently selected from the group consisting of H, loweralkyl, oxyalkyl, alkoxyalkyl, cycloalkyl, aryl, hydroxyalkyl, aminoalkyl, and alkylaminoalkyl; R 3 and R 4 are each independently selected from the group consisting of H, loweralkyl, halogen, oxyalkyl, oxyaryl, and oxyarylalkyl; R 5 is represented by a formula selected from the group consisting of: 2 wherein: X 1 , X 2 , and X 3 are independently selected from O and S; and R 6 and R 7 are independently selected from the group consisting of loweralkyl, aryl, alkylaryl, oxyaryl, an ester-containing substituent, and oxyalkyl; or a pharmaceutically acceptable salt thereof.

  一种治疗感染的方法包括给予公式（I）描述的化合物的治疗有效量：其中：X可以是O、S或NR′，其中R′为H或较低烷基；R1和R2可以独立地选择自H、较低烷基、氧烷基、烷氧基烷基、环烷基、芳基、羟基烷基、氨基烷基和烷基氨基烷基的群；R3和R4各自独立地选择自H、较低烷基、卤素、氧烷基、氧芳基和氧芳基烷基的群；R5由以下公式中选择：其中：X1、X2和X3独立选择自O和S；R6和R7独立选择自较低烷基、芳基、烷基芳基、氧芳基、含酯基取代基和氧烷基的群；或其药学上可接受的盐。
• [EN] PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMEDICAMENTS D'ANALOGUES GABA, LEURS COMPOSITIONS ET UTILISATIONS
  申请人：XENOPORT INC

  公开号：WO2004052844A1

  公开（公告）日：2004-06-24

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using pharmaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，前药的制药组合物和制备前药的方法。本发明还提供了使用GABA类似物的前药的方法以及使用前药的制药组合物治疗或预防常见疾病和/或障碍的方法。
• [EN] PRODRUGS OF GABA ANALOGS, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMEDICAMENTS D'ANALOGUES DE GABA, COMPOSITIONS ET UTILISATIONS DESDITS PROMEDICAMENTS
  申请人：XENOPORT INC

  公开号：WO2002100347A2

  公开（公告）日：2002-12-19

  The present invention provides prodrugs of GABA analogs, pharmaceutical compositions of prodrugs of GABA analogs and methods for making prodrugs of GABA analogs. The present invention also provides methods for using prodrugs of GABA analogs and methods for using phannaceutical compositions of prodrugs of GABA analogs for treating or preventing common diseases and/or disorders.

  本发明提供了GABA类似物的前药，前药的制药组合物以及制备GABA类似物前药的方法。本发明还提供了使用GABA类似物前药的方法以及使用前药的制药组合物治疗或预防常见疾病和/或疾病的方法。